GLP-1 Medications: The Next Chapter in Diabetes Care

Ozempic®. Wegovy®. Zepbound®. Just a few years ago, most people had never heard these names. Today, they're among the most talked-about medications in the world. While much of the public conversation has centered on weight loss, researchers believe that's only part of the story. Emerging research suggests GLP-1 medications may influence many aspects of metabolic health, including blood sugar control, heart health, liver disease, inflammation, and even how the body uses energy. Those discoveries are changing the way scientists think about diabetes and opening the door to new possibilities for prevention and treatment.

At the AdventHealth Translational Research Institute (TRI), researchers are helping answer some of the biggest questions surrounding these medications. "It's an exciting time," says Karen Corbin, PhD. "The more we study GLP-1 medications, the more we realize their potential extends far beyond weight loss." While weight loss is often the most visible result, researchers are discovering that these medications may also improve metabolic health in ways that weren't fully understood when they were first introduced.

Originally developed to help people with Type 2 diabetes manage blood sugar, GLP-1 medications mimic a naturally occurring hormone that helps the body release insulin when it's needed, slows stomach emptying, and increases feelings of fullness after eating. Their remarkable effectiveness in treating obesity quickly brought them into the national spotlight, but it also raised an important question: Could these medications be improving health in ways that go beyond helping people lose weight?

Researchers are now working to find those answers. Studies are exploring how GLP-1 medications affect the heart, liver, kidneys, muscles, brain, and other organs involved in metabolic health. Scientists are also investigating why some people respond better than others and whether these medications could help prevent or slow complications associated with diabetes and obesity. "Weight loss is certainly important," Dr. Corbin explains, "but we're also asking what these medications are doing at the cellular level and how they influence the body's overall metabolism."

Those questions are at the heart of clinical research. Every medical breakthrough begins with scientists asking why something works, who benefits the most, and how treatments can be improved. Through carefully designed clinical trials, researchers at TRI are helping build the evidence that may shape the next generation of diabetes care. Each study adds another piece to the puzzle, bringing researchers closer to more personalized approaches for preventing and treating chronic metabolic diseases.

Although GLP-1 medications have already transformed diabetes and obesity care, researchers believe we're only beginning to understand their full potential. Ongoing studies continue to explore how these medications work, who is most likely to benefit, and how they may be used to improve health beyond blood sugar and weight management.

"The questions we're asking today," says Dr. Corbin, "have the potential to improve care for patients for years to come."